The Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done.
When the FDA was deciding whether to approve the drug Tavneos several years ago to treat a set of rare autoimmune diseases, agency experts argued that would be a mistake, according to FDA records. One problem cited: The manufacturer had provided only “limited safety data.” As it often does, the FDA in 2021 approved the…